In the competitive and fast-moving world of inflammasome therapeutics, the field stands on the brink of a breakthrough – poised to deliver the first clinical proof-of-concept across a range of chronic and inflammatory diseases.

With companies like NodThera reporting promising results in Parkinson’s disease and obesity, and Shaperon, AC Immune, and Ventyx Biosciences advancing promising inflammasome-targeted programs, the race is heating up to bring first-in-class therapies to market.

That’s where the 7th Inflammasome Therapeutics Summit comes in – your dedicated platform to engage with 70+ drug developers, translational scientists, and clinical strategists pushing the boundaries of inflammasome research. Through real-world case studies, strategic insights, and collaborative discussions, you’ll gain actionable intelligence on everything from NLRP3 to non-canonical pathways.

Whether you’re progressing a clinical-stage candidate or exploring novel inflammasome biology, this summit equips you with the tools to optimize development strategy, mitigate risk, and accelerate time to clinic.